Antibodies against targets other than HLA antigens have been associated with AMR and allograft loss in solid organ transplantation. Detection of these antibodies has been hampered by the lack of available screening tools. This study aims to evaluate a Luminex® non-HLA antigen panel (Immucor® LNHA) for detection of antibodies against endothelial cell and tissue specific antigenic targets.Sera collected prior to and after transplantation from kidney recipients with a normal biopsy or normal function at follow-up (n=20) or an abnormal biopsy (AMR, tubular injury, CMR or microcirculation inflammation; n=14) and 4 commercially available negative control sera (NHS) were used for evaluation. The assay was performed according to Immucor LIFECODES Single antigen assay and acquired on a Labscan100. The cutoff for a positive result for each probe representing an antigenic target was determined based on the mean fluorescence intensity of the 4 NHS (mean MFI +/−1 SD). The ratio of test serum to negative control cutoff was calculated for each antigen (MFI test serum/ MFI NHS cutoff). Mean ratios were calculated across all or a subset of antigens and compared between these 2 patient cohorts.The mean ratio using pre-transplant sera for all 70 probes included in the panel was higher in the abnormal biopsy group compared to the normal group (0.87 (95% CI 0.80–0.93) versus 0.71 (95% CI 0.64–0.76) respectively; p=0.004). A comparison was also performed with a subset of 44 antigens that have been reported as targets for antibodies detected in the sera of patients with kidney disease. The mean ratio using pre-transplant sera remained higher in the abnormal biopsy group compared to normal group (0.89 versus 0.73; p=0.001). An even greater difference in the mean ratios between the 2 groups was observed using sera obtained at time of biopsy for the 70 probes (0.71 versus 0.48; p<0.001).Recipients with antibodies reactive with the non-HLA antigens represented in this panel strongly associated with abnormal biopsies. Importantly, this correlation with abnormal biopsies was found using both pre-transplant sera and sera obtained at time of biopsy.